San Diego-based aTyr Pharma (“aTyr”), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address rare diseases, announced today that Resolaris™ has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Resolaris, an investigational new drug representing aTyr’s first Physiocrine-based product… Read More »
aTyr Receives U.S. FDA Orphan Designation for FSHD drug
Volleyball fundraiser
By Russell Caratenuto III This May 6, I’m organizing an FSHD fundraiser with the East Brunswick High School boys volleyball team in order to raise awareness for FSHD. As I am personally affected by the disease, I was motivated to raise funds to help the fight against FSHD. Before my diagnosis, I had never heard… Read More »
Bone Health in FSHD–What do I need to know?
Special talk by Dr. Carla Grosmann from the Kennedy Krieger Institute Mid-Atlantic Patient Meeting Saturday, May 2, 2015. Noon-3:00 PM Will be live streamed over the FSH Society’s YouTube channel. Bone health is a topic that until recently has not been discussed in the context of FSHD, but we are beginning to realize that it is… Read More »
The very model of a modern epigenetic disease
Yes, we’re talking about FSHD On those rare occasions (such as the FSHD Connect meeting) when large numbers of individuals with FSHD gather in one place, one can’t help but be struck by how greatly symptoms vary from person to person. Some twentysomethings are in wheelchairs, while some septuagenarians are still walking with the aid… Read More »
Kelli O’Hara dazzles in “The King and I”
Congratulations to FSH Society honorary board member Kelli O’Hara for her much-anticipated debut in the role of Anna in the current Broadway revival of “The King and I.” The production premiered last night at New York’s Lincoln Center and won admiring reviews from the critics. Ben Brantley of the New York Times writes: “One look… Read More »